TRY MABLE.COM

Neurolytic Healthcare, Inc., trading under the name "Mable," is a health tech company founded in 2019 by Inna Nicole Thalmann and Roman Rothaermel (CEO), along with Chris Eijsbouts and Kumeren Govnder. Headquartered in California, Mable operates within the emerging field of genomics-based telehealth services, specifically focusing on migraine care. With the mission of revolutionizing the way neurological conditions are diagnosed and treated, the company integrates genetic and biomarker data into personalized healthcare plans for patients.

​

In 2022, the company secured a seed funding round of USD 3.2 million, led by Initialized Capital, with additional investments from Arkitekt Ventures, First In Capital, and individual investors. This funding was a crucial step in furthering the company's mission to combine advanced diagnostics with personalized treatment options.

​

Genomics-Based Telehealth for Migraine Care

​

Mable’s core offering is an innovative platform that blends genomics with telemedicine. The platform collected and analysed patients’ genetic and biomarker data, generating insights that inform individualized treatment plans. For migraine sufferers, who often face unpredictable symptoms and inconsistent treatment responses, this personalized approach offered the potential for more effective and targeted care.

​

Migraines are a complex neurological condition affecting millions globally. Traditional approaches to migraine management often rely on a trial-and-error method of prescribing medications, which can take time and may not yield optimal results. Mable aims to address this challenge by utilizing genomics to better understand a patient’s predisposition to migraines and how their body is likely to respond to various treatments.

​

How the Platform Works

​

Mable’s platform offers an entirely virtual experience, from consultations to diagnostics and treatment planning. Patients seeking care for migraines begin their journey with an online consultation, during which they share their medical history and symptoms. From there, Mable offers DNA testing services to gain insights into their genetic makeup.

​

By analysing genetic markers and biomarkers, Mable provides precision medicine options, offering treatments specifically tailored to the individual patient’s biological profile. This form of preventive care not only helps treat current symptoms but also aims to reduce the frequency and intensity of future migraines. Patients receive ongoing telehealth support to adjust treatments as necessary, based on their progress and changes in their condition.

​

Precision Medicine in Migraine Care

​

The use of genomics in healthcare, and particularly in migraine management, represents a shift toward precision medicine—a medical model that customizes healthcare, with decisions and treatments tailored to the individual patient. For migraine patients, this means that instead of a one-size-fits-all approach, Mable provides treatments that align with each patient’s unique genetic and biological characteristics.

​

This type of personalised care is particularly valuable in the treatment of neurological conditions like migraines, which often involve a complex interplay of genetic and environmental factors. By identifying the genetic underpinnings of a patient’s migraine condition, Mable can recommend treatments that are more likely to be effective based on their genetic profile, potentially improving outcomes and reducing the side effects of unnecessary medications.

​

Funding 

​

In July 2022, Neurolytic Healthcare, Inc. raised USD 3.2 million in seed funding, marking a significant milestone for the company. The investment was led by Initialized Capital, with additional backing from Arkitekt Ventures, First In Capital, and an individual investor. The funds are expected to support the expansion of Mable’s platform and services, enabling the company to refine its genomic analysis capabilities and broaden its reach within the telehealth and neurological care space.

​

As precision medicine continues to gain traction within the healthcare industry, Mable is positioned at the forefront of integrating genetic data into telehealth services for migraine patients. The company’s focus on genomic insights, combined with its digital platform, offers a forward-thinking approach to treating a condition that impacts the quality of life for so many individuals.

​

Neurolytic Healthcare, Inc., through its Mable platform, exemplifies the potential of combining genomics with telemedicine to create more personalized, effective treatments for migraines. By leveraging DNA and biomarker data, the company provides patients with precision care that could reduce the burden of migraines, offering a glimpse into the future of individualised treatment for neurological conditions.

More Reading:
Migraine: Diets And Food Triggers

Rimegepant (Nurtec) Migraine Medication
Sumatriptan Migraine Medication

​Can A Specific Diet Treat Migraine

Topiramate Migraine Medication​

Caffeine Withdrawal Headache

​

At My Hair UK, we are a renowned healthcare provider specialising in advanced hair restoration techniques. With our CQC-inspected hair transplant clinics in London and Manchester, we offer world-class treatments to individuals looking to enhance their hair and boost their self-esteem. Our experienced, GMC-registered surgeons perform Sapphire Blade FUE Hair Transplants in the UK, a minimally invasive procedure that ensures exceptional precision and delivers natural-looking, permanent results. Our goal is to help you regain a fuller, healthier head of hair, restore your youthful appearance, and increase your confidence.

​

Thanks to significant advances in technology, UK hair transplant costs are now more affordable than ever before. What was once considered an expensive luxury is now accessible to many people who wish to combat hair loss. Hair transplants in the UK are becoming increasingly cost-effective, providing a realistic option for individuals seeking to restore their hairline or fill in thinning areas. My Hair UK offers affordable, high-quality treatments, enabling you to achieve your hair restoration goals without the hefty price tag.

​

If you are struggling with hair loss and wondering whether a hair transplant could be the right solution for you, we offer a free consultation with our team of trichology experts. During this session, we will assess your unique hair loss pattern and provide a personalised treatment plan tailored to your specific needs. Whether you’re concerned about a receding hairline, thinning crown, or other areas of hair loss, My Hair UK is here to provide you with the care and results you deserve.